Switch 2%
Resmed Inc (RMD)
to
Clinuvel Pharmaceuticals Ltd (CUV)
*** GENERAL ADVICE ONLY ***
Description
Sector: Healthcare
Clinuvel Pharmaceuticals Limited excels in the study of melanocortins and their interaction with the human body, channeling this research into the creation of cutting-edge pharmaceutical and PhotoCosmetic products. Our specialization is deeply rooted in developing treatments that are primarily focused on skin health and the central nervous system. Through our dedicated research, Clinuvel has developed significant expertise in several key areas:
- Investigating the intricate relationship between visible and UV light with human biology.
- Gaining comprehensive knowledge of melanocortin peptides and their analogues.
- Advancing the use of hormonal therapies for the treatment of anti-inflammatory conditions and nervous disorders.
- Pioneering in controlled-release pharmaceutical formulations to improve treatment effectiveness and patient experience.
Metrics
Date: 29/1/2024
Market Cap: $767.45M
PE: 25.91
Yield: 0.33%
Trade
Allocation: 2% Entry: $15.5 Target: $24 Trim: $19 Stop: $12.5
Catalyst
With the recent run in RMD we are looking to bank some profits here at $29 (+20%) while we see further upside in the stock, the risk that further developments in the GLP-1 space could derail this recent run. Particularly a study due from Eli Lily a maker of Zepbound in the next month.
We still prefer exposure in the healthcare space and are recommending a switch of our RMD allocation to Clinuvel (CUV) a skin disease treatment for sufferers of EPP. They are also in Phase 2 of a stroke treatment drug which is looking promising
Disclaimer: The recommendation given is general advice only. It does not take into account your personal objectives, financial situation, or specific needs. This information should not be your sole resource when making such decisions. We strongly recommend you to seek the advice of financial, taxation, and legal professionals before finalising any investment decisions.